Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

References

• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476–87
   PubMed Web of Science ®Google Scholar
• Nygren P, Sørbye H, Østerlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005; 44: 203–17
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14
   PubMed Web of Science ®Google Scholar
• Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 2005; 23: 4553–60
   PubMed Web of Science ®Google Scholar
• Rougier, Lepere C. Second-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2005; 32(Suppl 9)S48–S54
   Google Scholar
• Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229–37
   PubMed Web of Science ®Google Scholar
• Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23: 7125–34
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhill SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243–9
   PubMed Web of Science ®Google Scholar
• Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–22
   PubMed Web of Science ®Google Scholar
• Sørbye H, Glimelius B, Berglund Å, Fokstuen T, Tveit KM, Brændengen M, et al. Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31–8
   PubMed Web of Science ®Google Scholar
• Sørbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003; 42: 827–31
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868–73
   PubMed Web of Science ®Google Scholar
• Glimelius B, Sørbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM, et al. Randomised phase III multicenter trial comparing irinotecan in combination with either the Nordic bolus 5FU and folinic acid (5FU/FA) schedule (FLIRI) or the bolus/infused de Gramont schedule (FOLFIRI), in patients with metastatic colorectal cancer. ECCO 13–The European Cancer Conference, Paris, France. Abstract 597, 2005.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Harrell FE. Regression modelling strategies: With applications to linear models logistic regression and survival analysis. Springer-Verlag, New York 2001
   Google Scholar
• Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308–17
   PubMed Web of Science ®Google Scholar
• Bensmaine MA, Marty M, de Gramont A, Brienza S, Levi F, Ducreux M, et al. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)±folinic acid in a compassionate-use cohort of 481 5-FU resistant advanced colorectal cancer patients. Br J Can 2001; 85: 509–17
   PubMed Web of Science ®Google Scholar
• Mitry E, Douillard JY, van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013–7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhonen S, James RD, Punt C, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–8
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta C, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuos infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12
   PubMed Web of Science ®Google Scholar
• Rothenburg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059–69
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269–72
   PubMed Web of Science ®Google Scholar
• Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G, et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anti-Cancer Drugs 2003; 14: 745–9
   PubMed Web of Science ®Google Scholar
• Recchia F, Saggio G, Nuzzo A, Lalli A, Di Lullo L, Cesta A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Can 2004; 91: 1442–6
   PubMed Web of Science ®Google Scholar
• Mabro M, Louvet C, Andre T, Carola E, Gilles-Amar V, Artru P, et al. Bimonthly leucovorin, infusional 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003; 26: 254–8
   PubMed Web of Science ®Google Scholar
• Mabro M, Artru P, Andre T, Flesch M, Maindrault-Goebel F, Landi B, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287–92
   PubMed Web of Science ®Google Scholar
• Blanke CD. Whither irinotecan?. J Clin Oncol 2005; 23: 4811–4
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg 2004; 240: 644–58
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005; 16: 425–9
   PubMed Web of Science ®Google Scholar